Interested in submitting an e–Pearl? Click here!
Brought to you by the Resident and Fellow Section of Neurology®.
March 6, 2012
CSF levels of tau and Aβ42 are well known markers of Alzheimer disease. Recently, Visinin–like protein–1, which is a highly expressed neuronal calcium–sensor protein, has been shown to not only be a marker of neuronal injury, but also a potential marker of annual cognitive decline. Visinin–like protein–1, also known as VILIP–1, has been detected in close association with amyloid plaques, but does not appear to be a component of neurofibrillary tangles. In the study cohort featured in this week’s issue, VILIP–1 predicted future cognitive decline in early Alzheimer disease over the follow–up period at least as well as tau and Aβ42, supporting the potential utility of CSF VILIP–1 as a biomarker for neurodegeneration in AD.
1. Tarawneh R, MD, Lee J–M, Ladenson JH, Morris JC, and Holtzman DM. CSF VILIP–1 predicts rates of cognitive decline in early Alzheimer disease. Neurology 2012; 78: 709–719.
2. Galasko D, Chang L, Motter R, et al. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 1998; 55: 937–945.
Submitted by: Stacey L. Clardy, MD, PhD
Disclosures: Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section.
For more clinical pearls and other articles of interest to neurology trainees, visit www.neurology.org and click on the link to the Resident and Fellow Pages. Click here to visit the E–Pearl of the Week Archive.
Click here to listen to this week's Neurology® Podcast.